The earnings call presented a mix of positive growth in product sales and strategic improvements in the German market, alongside significant regulatory challenges with the DrugSorb ATR product. While operational costs have increased, the company is optimistic about its appeal processes and potential future growth.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call for Cytosorbents Corp, the company provided several key metrics and updates. Product sales for the second quarter were reported at $9.6 million, marking a 9% year-over-year increase and a 4% rise on a constant currency basis. The German commercial team saw a significant 22% growth both year-over-year and sequentially, reflecting the positive impact of the company's strategic realignment efforts. Gross margin held steady at 71%, despite challenges from inventory write-offs. Operating expenses were slightly higher than the previous year, primarily due to unique charges, including regulatory legal consulting expenses, and costs associated with commercial restructuring and DrugSorb ATR commercialization planning. The company is targeting near breakeven for its core business by the end of 2025, with sufficient cash to support ongoing initiatives. Additionally, Cytosorbents anticipates final regulatory decisions for its DrugSorb ATR device from both the FDA and Health Canada by the end of the year, with a potential market opportunity exceeding $1 billion.

Strong Product Sales Growth

Q2 2025 product sales were $9.6 million, representing a 9% year-over-year increase and up 4% on a constant currency basis.

German Market Recovery

The German commercial team grew 22% year-over-year and sequentially in the quarter, indicating positive results from strategic reorganization.

High Gross Margin Maintained

Gross margin performance remained solid, holding steady at approximately 71%.

Promising Sepsis Treatment Results

New publications and studies show CytoSorb significantly improves outcomes in patients with septic shock, reducing mortality and improving hemodynamic stability.

Cytosorbents (CTSO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CTSO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.04 / -	-0.04	―	―	―
Aug 07, 2025	2025 (Q2)	-0.05 / 0.03	-0.08	137.50% (+0.11)	―
May 14, 2025	2025 (Q1)	- / -0.02	-0.12	83.33% (+0.10)
Mar 31, 2025	2024 (Q4)	-0.07 / -0.02	-0.12	83.33% (+0.10)
Nov 07, 2024	2024 (Q3)	-0.06 / -0.04	-0.21	80.95% (+0.17)
Aug 13, 2024	2024 (Q2)	-0.10 / -0.08	-0.14	42.86% (+0.06)
May 09, 2024	2024 (Q1)	-0.12 / -0.12	-0.17	29.41% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.14 / -0.12	-0.01	-1100.00% (-0.11)	―
Nov 09, 2023	2023 (Q3)	-0.12 / -0.21	-0.28	25.00% (+0.07)	―
Aug 01, 2023	2023 (Q2)	-0.11 / -0.14	-0.25	44.00% (+0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CTSO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.89	$1.00	+12.36%
May 14, 2025	$0.81	$0.83	+2.47%
Mar 31, 2025	$1.00	$1.00	0.00%
Nov 07, 2024	$0.90	$0.74	-17.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cytosorbents Corp (CTSO) report earnings?

Cytosorbents Corp (CTSO) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Cytosorbents Corp (CTSO) earnings time?

Cytosorbents Corp (CTSO) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CTSO EPS forecast?

CTSO EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing